We are in the process of developing a method of delivering an amyloid-beta plaque inhibitor via a transdermal patch, as a component of a combination therapy similar to our ALZT-OP1 product candidate. We refer to this product under development as our ALZT-Patch. We believe that transdermal delivery may enable more consistent dosing and better drug compliance among early AD patients than delivery by inhalation. The drug to be delivered by the ALZT-Patch will be a new, proprietary formulation of an amyloid-beta plaque inhibitor chosen from a series of pro-drug compounds, derived from the chemical structure of ALZT-OP1a and having better skin penetration. We expect to file an Investigational New Drug Application, or IND, for the ALZT-Patch with the FDA by mid 2017.